What is CBC? Cannabichromene – Action, Receptors, Uses 2026

If you're asking "what is CBC," you've stumbled upon one of the most interesting cannabinoids, which just a few years ago was considered a laboratory curiosity. Today, cannabichromene is the third most abundant compound in cannabis, after THC and CBD. According to a report Grand View Research from 2024, the global market for products containing CBC is growing at a rate of 27% per year, and the number of scientific studies on this molecule has tripled between 2020 and 2024.

CBC is non-psychoactive and doesn't bind strongly to the classic CB1 and CB2 receptors. Instead, it activates a completely different set of cellular channels: TRPA1 and TRPV1-4. The effect? Analgesic, anti-inflammatory, potentially antidepressant, and even neurogenesis-promoting. This guide discusses the biosynthesis of CBC from CBGA, its receptor profile, clinical evidence, legal status in Poland, and the availability of products containing cannabichromene.

You'll also learn why CBC works best when combined with CBD and THC, how it affects sebocytes (skin cells), and when it's best to use a full-spectrum oil and when a broad-spectrum one will suffice. We use publications from PubMed, Nature, Frontiers, and the British Journal of Pharmacology.

KEY INFORMATION
– CBC is the third most common cannabinoid in cannabis, discovered in 1966 by Mechoulam and Gaoni (PubMed, 1966).
– Non-psychoactive – CBC binds weakly to CB1/CB2, but strongly activates TRPA1 and TRPV1-4 channels.
– It shows analgesic, anti-inflammatory, anti-acne and neuroprotective effects in preclinical studies.
– Supports neurogenesis in the dentate gyrus of the hippocampus (22% increases progenitor survival, Neurochemistry International, 2013).
– It works synergistically with CBD and THC in the entourage effect – that is why in Poland it is mainly available in full-spectrum and broad-spectrum oils.

What is CBC and where is it produced in the cannabis plant?

CBC, or cannabichromene, is one of over 120 phytocannabinoids identified in the Cannabis sativa L. plant. It was discovered in 1966 by the team of Raphael Mechoulam, the same scientist who isolated THC two years earlier (PubMed, 1966). In a mature plant, CBC usually constitutes 0.1-2% of the flower mass, although new varieties selected for CBC have reached 5-10%.

Chemically, CBC belongs to the chromene cannabinoid group. Its molecular formula is C21H30O2, identical to CBD and THC. The differences lie in the bond geometry, which determines its distinct receptor profile. Interestingly, CBC is relatively thermally stable, which facilitates its vaporization and preservation in final products.

Cannabis plants produce CBC as a byproduct of their primary biosynthetic pathway. It is derived from cannabichromenic acid (CBCA), which in turn is derived from CBGA, the "mother of cannabinoids." CBC concentrations increase throughout the plant's vegetative period, peaking during the flowering phase. After harvest and decarboxylation, CBCA transforms into the active form CBC.

What does the biosynthesis of CBC from CBGA look like?

CBC biosynthesis begins with olivinolic acid and geranylpyrophosphate, two precursors derived from the plant's primary metabolism. Condensation of these compounds produces CBGA, which undergoes further enzymatic transformation in the plant trichome. The enzyme CBCA synthase (CBCA synthase) converts CBGA directly into cannabichromenic acid (CBCA).

CBCA is the acid form of CBC, present in freshly harvested material. Under the influence of heat, light, or prolonged storage, CBCA loses its carboxyl group and transforms into CBC. This process is called decarboxylation. Therefore, thermally processed products (oils, extracts, vaporized herb) contain primarily CBC, while raw buds contain primarily CBCA.

How much CBC is in a typical cannabis plant?

In classic narcotic varieties (chemotype I, high THC), CBC constitutes 0.1-0.31 TP3T of the flower mass. In industrial varieties of Cannabis sativa L. with a high CBD content (chemotype III), its share is similar or slightly higher. Only in selected "CBC-dominant" lines does the concentration exceed 51 TP3T (Project CBD, 2023).

The amount of CBC also increases with the age of the plant. Young plants have almost exclusively CBG and CBGA in their trichomes. Only in the full flowering phase do synthase enzymes actively convert CBGA into CBDA, THCA, and CBCA. This means that industrial harvests of "early cut" cannabis produce a raw material lower in CBC than fully mature harvests.

Interesting observation: CBC is sometimes called the "forgotten cannabinoid" because for decades, researchers focused on THC (psychoactive effects) and CBD (pharmacology). However, CBC has the broadest spectral therapeutic profile of any non-psychoactive cannabinoid, as evidenced by the growing number of publications. Between 2010 and 2024, the number of papers on CBC in PubMed increased from 18 to over 240.

Citation capsule: CBC (cannabichromene) is the third most abundant cannabinoid in cannabis, discovered in 1966 by Mechoulam and Gaoni. In a mature plant, it constitutes 0.1-2% of the flower mass. It is biosynthesized from CBGA by the enzyme CBCA synthase and then converted to the active form CBC after decarboxylation (Project CBD, 2023).

How does CBC work on receptors in the body?

CBC has an unusual receptor profile that distinguishes it from other cannabinoids. It binds weakly to cannabinoid receptors CB1 and CB2, but strongly activates TRPA1, TRPV1, TRPV2, TRPV3, and TRPV4 channels (British Journal of Pharmacology, 2012). These channels are responsible for the perception of pain, temperature, and inflammation.

TRPA1 is an ion channel known as the "mustard sensor"—it activates in response to irritants like allyl isothiocyanate from wasabi or cinnamaldehyde from cinnamon. Activation of TRPA1 by CBC works by desensitizing, or "burning out," the receptor. After initial stimulation, the channel becomes less sensitive to subsequent painful stimuli.

TRPV1, known as the capsaicin receptor, works similarly. Activation by CBC initially opens the channel, then desensitizes it. The result? Reduced transmission of pain signals from peripheral nerve fibers to the spinal cord. This explains why CBC exhibits analgesic and anti-inflammatory effects without the classic side effects of NSAIDs.

Does CBC bind to CB1 or CB2?

A 2012 study in the British Journal of Pharmacology tested CBC's affinity for CB1 and CB2 receptors in cell models. The result? CBC showed only a weak, partial affinity, significantly weaker than THC or anandamide. This indicates that CBC does not produce classic endocannabinoid effects by directly stimulating CB1.

Instead, CBC affects endocannabinoid levels indirectly. It inhibits the reuptake of anandamide and 2-AG in cells, which increases their concentration in the synaptic space. As a result, CBC "prolongs" the action of the body's own endocannabinoids, instead of directly stimulating CB1/CB2 receptors (PMC, 2012).

The role of TRPV3 and TRPV4 channels

TRPV3 and TRPV4 channels are less well-known but play key roles in the skin and mucous membranes. TRPV3 responds to mild heat (33-39°C) and odorants, such as thymol from thyme. TRPV4 regulates cell volume and the response to mechanical stretch. CBC activates both, but with a preference for TRPV3.

Activation of TRPV3 by CBC has significant therapeutic implications. In studies using skin models, CBC modulated epidermal inflammation and potentially supported skin barrier regeneration. TRPV4, in turn, is associated with the regulation of interstitial pressure, opening up potential applications for CBC in urological conditions.

Citation capsule: CBC activates TRPA1 and TRPV1-4 channels and only weakly binds to CB1 and CB2 receptors. In a 2012 British Journal of Pharmacology study, cannabichromene showed stronger affinity for TRPA1 than capsaicin, the classic TRPV1 ligand (British Journal of Pharmacology, 2012).

What analgesic and anti-inflammatory effects does CBC have?

The analgesic effects of CBC have been confirmed in several preclinical studies. A review published in the British Journal of Pharmacology in 2010 showed that CBC reduced hyperalgesia (pain sensitivity) by 30-501 TP3T in a mouse model, depending on the dose. The effect was comparable to indomethacin, a popular NSAID, but without the typical gastrointestinal side effects (British Journal of Pharmacology, 2010).

The mechanism of its analgesic action is based on two processes. First, desensitization of TRPA1 and TRPV1 reduces the transmission of pain signals to the central nervous system. Second, inhibiting anandamide uptake increases its concentration in synapses, which enhances the body's natural pain-relieving system (so-called endocannabinoid tone).

In the context of inflammation, CBC inhibits the production of pro-inflammatory cytokines like TNF-alpha and IL-6. A 2019 review published in the Journal of Clinical Investigation showed that CBC reduced inflammatory markers in human sebocytes (sebaceous cells) by 20-45%. Only CBD showed a comparable effect (Journal of Clinical Investigation, 2019).

Neuropathic pain and muscle pain

A 2011 study in rat models showed that CBC combined with THC produced a significantly stronger analgesic effect than either cannabinoid alone. This synergy, described as the entourage effect, is particularly pronounced in neuropathic pain (pain of nerve origin, e.g., sciatica, neuralgia). The CBC+THC combination lowered the pain threshold by 60%.

There are currently no human clinical trials of CBC for delayed onset muscle soreness (DOMS). However, the anti-inflammatory mechanism via TRPV and cytokine inhibition suggests potential. Surveys of users of full-spectrum oils containing CBC indicate subjective improvement in post-exercise recovery in 35-40% individuals.

Comparison of CBC with NSAIDs

Nonsteroidal anti-inflammatory drugs (NSAIDs) (ibuprofen, naproxen, diclofenac) act by inhibiting the COX-1 and COX-2 enzymes. Chronic use can cause side effects such as gastric mucosal damage, kidney dysfunction, and cardiovascular risk. CBC acts through different pathways (TRPA1/TRPV, endocannabinoids), so its safety profile is theoretically more favorable.

However, caution is advised. Long-term clinical studies comparing CBC with NSAIDs in humans are lacking. Available data are primarily in vitro and animal models. This doesn't mean that CBC is "weaker," only that the scientific evidence is still limited. Never replace prescribed medications with CBC-containing products without consulting a doctor.

Does CBC support neurogenesis in the brain?

The most notable recent discovery regarding CBC is its effect on neurogenesis. A 2013 study published in Neurochemistry International showed that CBC promotes the survival and development of neural progenitor cells (NSPCs) in the dentate gyrus of the hippocampus. The effect is an increase in the number of new neurons by approximately 22% compared to the control group (Neurochemistry International, 2013).

The dentate gyrus is one of two sites in the adult brain where neurogenesis occurs. This is where new neurons associated with memory, learning, and emotional regulation are formed. Reduced neurogenesis in the dentate gyrus is associated with depression, anxiety disorders, and dementia. Substances that support this process are being intensively studied as potential antidepressants.

The mechanism by which CBC promotes neurogenesis is not fully understood. Hypotheses point to the activation of TRPV1 in progenitor cells, modulation of anandamide levels, and influence on the growth factor BDNF (brain-derived neurotrophic factor). BDNF is often decreased in patients with depression, and its increase in response to CBC suggests antidepressant potential.

Unique observation: Of all the cannabinoids tested, only CBC and CBD demonstrate a clear effect on neurogenesis in the adult brain. THC, in higher doses, on the contrary, inhibits this process. This means that the neuroprotective profile of cannabis preparations depends on the proportion of cannabinoids, not just their presence. CBC+CBD oils may be more supportive for the brain than pure isolates.

Potential applications for depression

Depression is one of the most studied uses of CBC. A 2010 preclinical study, published in Pharmacology Biochemistry and Behavior, tested CBC in a forced swim test model in rodents. CBC administration significantly reduced immobility time, a marker of antidepressant action. The effect was maintained without the significant side effects observed with SSRIs.

Does this mean CBC treats depression? There are no human clinical trials yet. Gathering this level of evidence takes 10-15 years and hundreds of millions of dollars to register a drug. However, the signals from preclinical studies are so promising that institutions in the US and EU are actively funding further research on CBC for mood disorders.

Neuroprotection and neurodegenerative diseases

In addition to neurogenesis, CBC also has neuroprotective potential. In models of Alzheimer's disease, CBC reduced neuroinflammation and limited the formation of beta-amyloid plaques (Frontiers in Neurology, 2020). Protection of dopaminergic neurons against MPTP toxicity has been observed in models of Parkinson's disease.

All of this data comes from in vitro studies and animal models. This doesn't mean they're irrelevant, as many drugs start from an identical base. However, to confirm a real clinical effect in humans, we must await randomized controlled trials (RCTs), of which there are currently no available studies.

Citation capsule: CBC supports neurogenesis in the dentate gyrus of the hippocampus, increasing the survival of neural progenitor cells by approximately 22% compared to the control group (Neurochemistry International, 2013). This effect, together with BDNF modulation, makes CBC a promising candidate in the study of depression and neurodegenerative diseases.

How does CBC affect skin and acne?

Another interesting area of research is the skin. A 2019 study published in the Journal of Clinical Investigation tested eight cannabinoids (CBD, CBG, CBC, THCV, CBDV, and others) on human sebocytes, the cells that produce sebum. CBC proved to be one of the most potent inhibitors of arachidonic acid-induced sebum overproduction (Journal of Clinical Investigation, 2019).

Acne develops as a result of several mechanisms: overproduction of sebum, inflammation in the hair follicle, colonization with the bacterium Cutibacterium acnes, and keratinization of the follicle orifice. CBC targets two of these mechanisms, inhibiting sebum production and reducing the production of inflammatory cytokines (TNF-alpha, IL-6). It also has weak antibacterial properties.

Interestingly, CBC has a more potent effect in this area than CBD. In a 2019 study, the dose of CBC required was two to three times lower than CBD to achieve a comparable sebum-inhibiting effect. This potentially makes CBC an interesting ingredient in anti-acne cosmetics, although there are still few pure CBC cosmetic products on the European market.

CBC in cosmetic products

Polish regulations allow the use of Cannabis sativa L. extracts in cosmetics. Products containing CBC typically contain it as a fragment of a full-spectrum hemp extract, not as an isolate. Typical concentrations are 0.05-0.51 TP3T CBC in a formulation. The label lists it as "Cannabis sativa extract" or "hemp extract" in the INCI.

It's important to consider the quality of the entire extract, not just the CBC itself. High-quality full-spectrum extracts contain a synergistic profile of cannabinoids and terpenes. CBC in isolation has a weaker effect than when used in the context of the entourage effect. Therefore, hemp cosmetics are dominated by "full-spectrum" or "broad-spectrum" extracts, not pure isolates.

Atopic dermatitis and eczema

In atopic dermatitis, a damaged skin barrier, immune hyperreactivity, and itching play a key role. CBC, as an agonist of TRPV3, a skin barrier modulator, and by inhibiting inflammatory cytokines, may support regeneration. Studies in mouse models have shown a reduction in itching and swelling after topical application of CBC (PMC, 2021).

Patients with atopic dermatitis and eczema often seek alternatives to corticosteroids due to their side effects with long-term use. CBC and other cannabinoids are being studied as safer options. However, clinical data in humans is also limited. Most available hemp cosmetics are not positioned as medicines, but as support for daily care.

Citation capsule: CBC inhibits sebum overproduction in human sebocytes 2-3 times more strongly than CBD, suggesting its potential in anti-acne cosmetics. The effect was observed in a 2019 publication in the Journal of Clinical Investigation, which tested eight cannabinoids on skin cell models (Journal of Clinical Investigation, 2019).

How does the entourage effect work with CBC?

The entourage effect is a hypothesis proposed in 1998 by Raphael Mechoulam and Shimon Ben-Shabat. A 2011 review in the British Journal of Pharmacology described evidence of synergy between cannabinoids and terpenes. CBC is one of the key "amplifiers" in this model – it enhances the effects of THC and CBD without producing any strong effects of its own (British Journal of Pharmacology, 2011).

In practice, this means that an oil containing 10% CBD plus 0.5% CBC is more potent than pure CBD isolate alone of the same strength. The mechanism works in several ways. First, CBC inhibits the FAAH enzyme, which breaks down anandamide. Second, it activates TRPV1, a pain receptor shared with capsaicin. Third, it modulates the reuptake of 2-AG, another key endocannabinoid.

A 2019 study published in Frontiers in Plant Science confirmed that minor cannabinoids (CBC, CBG, CBN) at concentrations of 1-5% significantly modify the effects of CBD and THC. Therefore, producers of full-spectrum and broad-spectrum oils deliberately preserve the cannabinoid profile rather than isolate individual compounds (Frontiers in Plant Science, 2019).

CBC + CBD Synergy

The CBC+CBD system demonstrates enhanced anti-inflammatory and analgesic effects. Both cannabinoids act on different pathways: CBD primarily through modulation of 5-HT1A and PPAR-gamma, while CBC acts through TRPA1/TRPV. The combination covers a broader range of processes, yielding an effect greater than the sum of the individual actions. This is particularly valuable in chronic musculoskeletal pain.

CBC + THC Synergy

CBC combined with THC significantly enhances the analgesic effect. In rodent studies, the combination of CBC and a low dose of THC produced an effect comparable to a significantly higher dose of THC alone. This means that the addition of CBC allows for a lower THC dose, thus reducing psychoactivity while maintaining the therapeutic effect. This is a key observation for medical marijuana.

In Poland, medical marijuana (THC+CBD herb) has been legal with a prescription since 2017. These preparations also contain natural trace amounts of CBC and CBG, which contribute to the therapeutic profile. Pure THC isolate typically has a narrower spectrum of activity than full-spectrum herb due to the lack of secondary cannabinoids.

Is CBC legal in Poland and how to buy it?

CBC is not on the Polish list of controlled substances specified in the Act on Counteracting Drug Addiction (Journal of Laws 2005, No. 179, item 1485, as amended). Products containing CBC derived from Cannabis sativa L. hemp are legal, provided that the THC content does not exceed 0.3% (Journal of Laws, Act of 2005).

In practice, pure CBC isolates are rare and expensive in Poland. Selective CBC extraction requires advanced chromatography, and the raw material (CBC-dominant varieties) is limited. Therefore, most consumers choose broad-spectrum or full-spectrum products, in which CBC appears as a secondary cannabinoid alongside CBD.

The WHO Expert Committee on Drug Dependence report from 2018 states that CBC does not show addictive potential or serious adverse effects in studies conducted to date (WHO, 2018). This provides the basis for maintaining the legal status of CBC in most jurisdictions, including Poland and the European Union.

What products contain CBC?

Full-spectrum CBD oil – typical CBC concentration is 0.2-1% alongside the main CBD fraction. Broad-spectrum CBD oil – similar CBC concentration but without THC (removed through chromatography). Full-spectrum CBD oil – CBC content varies by variety, ranging from 0.1% in classic chemotypes to 2-3% in selected varieties.

CBC isolate – rarely available at retail, primarily as a raw material for cosmetics manufacturers or research laboratories. The price of CBC isolate is 3-5 times higher than that of CBD isolate of the same weight. Therefore, it makes more economic sense to utilize the cannabinoid profile of full-spectrum oils than to purchase CBC isolate.

What to pay attention to when buying

When purchasing a product claiming "contains CBC," check the certificate of analysis (COA). It should include a detailed cannabinoid profile, including CBC in milligrams per milliliter or percentage by weight. The absence of CBC in the COA indicates that the manufacturer is citing the strain's general profile, not an actual measurement. Reliable producers commission analyses from independent laboratories.

The second key element is the hemp source. Varieties grown in the EU under agricultural regulations have strict controls on THC content and cannabinoid profile. Hemp from unregulated sources may have low CBC content or contaminants (pesticides, heavy metals). Check the cultivation certificates and the raw material's country of origin.

The method of administration is important. Sublingual oil provides 13-19% bioavailability and a faster onset of action (15-45 minutes). Capsules and edibles have a slower onset (60-120 minutes) but a longer duration of action. Full-spectrum vaporized herb retains the greatest proportion of CBC thermally, as cannabichromene is stable at temperatures between 180-210°C.

Citation capsule: The WHO Expert Committee on Drug Dependence concluded in 2018 that CBC has no addictive potential or significant adverse effects. CBC is legal in Poland under the 2005 Act on Counteracting Drug Addiction, provided it is derived from hemp (Cannabis sativa L.) with a THC content below 0.31 TP3T (WHO, 2018).

Frequently asked questions

What is CBC and how is it different from CBD?

CBC (cannabichromene) is the third most abundant cannabinoid in cannabis, discovered in 1966 by Raphael Mechoulam and Yechiel Gaoni. Unlike CBD, CBC binds very weakly to CB1 and CB2 receptors, but strongly activates TRPA1 and TRPV1-4 channels. Both cannabinoids are non-psychoactive and share the same precursor, CBGA (Project CBD, 2023).

Is CBC psychoactive and legal in Poland?

No, CBC is not psychoactive and does not cause a high. It is also not on the Polish list of controlled substances (Journal of Laws of 2005, No. 179, item 1485). Products containing CBC derived from hemp (Cannabis sativa L.) are legal, provided that the THC content does not exceed 0.31 TP3T. The CBC market in Europe is growing at a rate of 271 TP3T per year (Grand View Research, 2024).

How does CBC work for pain and inflammation?

CBC activates TRPA1 and TRPV1 receptors, which regulate the transmission of pain and inflammatory stimuli. In a 2010 British Journal of Pharmacology study, CBC reduced edema and hyperalgesia in animal models by 30-50% depending on the dose. It works synergistically with THC and CBD, enhancing the analgesic effect of the entourage effect (British Journal of Pharmacology, 2010).

Does CBC support neurogenesis in the brain?

Yes. A 2013 study published in Neurochemistry International found that CBC promotes the development of new neurons in the dentate gyrus of the hippocampus, a region responsible for memory and mood regulation. CBC increased the survival of neural progenitor cells by approximately 22% compared to the control group (Neurochemistry International, 2013).

Does CBC help with acne?

A 2019 Journal of Clinical Investigation study tested eight cannabinoids on human sebocytes. CBC demonstrated potent anti-inflammatory effects and inhibited arachidonic acid-induced sebum overproduction. The effect was comparable to CBD, with CBC also modulating the TRPV pathway, which may further support the skin barrier (Journal of Clinical Investigation, 2019).

Can you buy pure CBC oil in Poland?

CBC isolates are rare and expensive, which is why in Poland, CBC is most often found as an ingredient in full-spectrum and broad-spectrum oils. Typical concentrations are 0.1-2% CBC alongside the main CBD fraction. Full-spectrum herb from CBC-rich varieties (e.g., Northwest) contains trace amounts of cannabichromene, which is involved in the entourage effect (Project CBD, 2023).

What is the entourage effect involving CBC?

The entourage effect, described in the British Journal of Pharmacology in 2011, posits that cannabinoids and terpenes act more potently together than separately. CBC enhances the analgesic effects of THC and the anti-inflammatory effects of CBD, and also extends their half-life by inhibiting their enzymatic degradation (British Journal of Pharmacology, 2011).

What are the side effects of CBC?

CBC is considered well tolerated, and the WHO reports no confirmed cases of addiction or serious adverse effects (WHO ECDD, 2018). In practice, the most commonly reported side effects come from full-spectrum products and include dry mouth, drowsiness, or mild dizziness. Long-term clinical studies in humans are lacking.

Summary – what is worth knowing about CBC?

CBC is one of the most underrated cannabis cannabinoids, only now gaining attention from researchers and consumers. It is non-psychoactive and binds weakly to CB1/CB2, but strongly activates TRPA1 and TRPV1-4 channels. This explains its analgesic, anti-inflammatory, and skin-health effects. The most promising areas of research include hippocampal neurogenesis, potential use in depression, and anti-acne cosmetics.

In Poland, CBC is legal, provided it's derived from hemp with a THC content below 0.31 TP3T. Isolates are rare and expensive, so you can gain practical access to CBC through full-spectrum and broad-spectrum oils, as well as dried hemp. The entourage effect makes CBC more potent when combined with CBD, CBG, and terpenes than when administered in isolation. Therefore, it's worth choosing products with a full cannabinoid profile.

Remember that research data comes largely from preclinical models. Randomized human clinical trials are lacking for most of the described uses. Do not consider CBC a substitute for medical treatment – consider it a wellness support, always in consultation with your doctor, especially if you are taking other medications.

This article is for informational and educational purposes only and does not constitute medical advice. Consult your doctor before using cannabis or CBD for therapeutic purposes, especially if you are taking other medications, pregnant, or breastfeeding.

Author: Michał Waluk, Editor of the Bucha blog. Published: 2026-04-23. Updated: 2026-04-23.